title: Recurrence of IgA nephropathy and Henoch-Schönlein purpura after kidney transplantation: risk factors and graft survival.
abstract: BACKGROUND
  IgA nephropathy (IgA) is one of the most common glomerulonephritis. Renal transplantation is the treatment of choice for patients with ESRD due to any kind of glomerulopathy, including IgA and Henoch-Schönlein purpura nephritis (H-SP), but original disease recurrence is now the third most frequent cause of allograft loss.
  
  
  METHODS
  Eighty-seven cases of glomerulonephritis as the original disease were divided in two groups: group A--37 affected with 31 IgA and 6 H-SP; and group B--50 with other glomerulopathies. We compared patient and graft survivals at 5 years. To assess the presence of IgA or H-SP recurrence in group A patients, we performed an allograft biopsy in the presence of microhematuria, proteinuria, or an increased plasma creatinine. Known risk factors influencing recurrence rate were also analyzed.
  
  
  RESULTS
  Five-year patient (97% vs 95%) and graft survivals (81% vs 78%) were not significantly different between groups A and B. Patients with crescentic glomerulonephritis (CGN) at the moment of diagnosis of IgA or H-SP showed a 5-year graft survival of 71% in contrast with 100% graft survival among those with mesangial or focal and segmental glomerulosclerosis pattern (P = .03). Histological recurrence was diagnosed in eight patients: six IgA and two H-SP. Women (P = .013) and a good HLA match (P = .029) were significantly associated with the risk of recurrence.
  
  
  CONCLUSIONS
  When compared with other glomerulonephritis patients, with IgA or S-HP showed similar 5-year graft and patient survivals. Nevertheless, graft survival was shorter among patients with crescentic glomerulonephritis at the moment of diagnosis. Thus, the disease prognosis after grafting may be linked to the initial histological aggressiveness. Women and those patients transplanted with a good HLA match were prone to develop disease recurrence with a tendency toward a lower 5-year graft survival.
authors.affiliation: Nephrology Department, Hospital del Mar, Universtat Autonoma de Barcelona, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: Soler
authors.forename: M
authors.initials: M
authors.lastname: Mir
authors.forename: E
authors.initials: E
authors.lastname: Rodriguez
authors.forename: A
authors.initials: A
authors.lastname: Orfila
authors.forename: A
authors.initials: A
authors.lastname: Munne
authors.forename: S
authors.initials: S
authors.lastname: Vázquez
authors.forename: J
authors.initials: J
authors.lastname: Lloveras
authors.forename: J M
authors.initials: JM
authors.lastname: Puig
mesh_terms: D000328:Adult; D002102:Cadaver; D005260:Female; D005500:Follow-Up Studies; D005922:Glomerulonephritis, IGA / Q000175:diagnosis*; D006085:Graft Survival; D006801:Humans; D011695:IgA Vasculitis / Q000175:diagnosis*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000401:mortality / Q000502:physiology; D019520:Living Donors; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D014019:Tissue Donors